ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - (Asymptoleish)

ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - POSTULATE PRIOR TO HUMAN VACCINAL TRIALS Immune Response of Asymptomatic Carriers to L. Infantum

Leishmaniasis is considered by the WHO as emerging and uncontrolled diseases. They are the second leading cause of death and the fourth leading cause of morbidity in tropical diseases. Leishmaniasis is parasitic reticulo-endotheliosis, the pathogenic agent of which is a flagellated protozoan belonging to the genus Leishmania. It is estimated that there are about 2 million new cases per year. Effective treatments against visceral leishmaniasis are few and resistance problems appear. To date, only a canine vaccine is available protecting dogs from the development of canine leishmaniasis to L. infantum. In man, in parallel clinical cases, leishmaniasis is characterized by a large number of asymptomatic carriers. This is the case in the Alpes-Maritimes where 50% of the inhabitants of the hinterland of Nice are carriers of the parasite.

the investigators wish to study the protective immune response to the parasite and more particularly to the asymptomatic carriers. Indeed, these patients were infected with the parasite and did not develop the disease. Understanding the protective immune response in these patients against the parasite is therefore paramount in the development of a human leishmaniasis vaccine.

For this purpose, the investigator wants to make an ex vivo study of the immune response of lymphocytes coming from asymptomatic carriers after stimulation by Leishmania vaccine peptides. It also wants to describe the immune response, after stimulation by these peptides, in the lymphocytes of subjects asymptomatic carriers and lymphocytes from subjects not infected with the parasite and comparing them. This study is unicentric and non-randomized. It wishes to recruit 20 asymptomatic carriers of L. Infantum and 10 uninfected subjects. They will be selected from our database. A simple blood sample will be taken. After verification by quantitative PCR and western blotting of their status towards leishmaniasis, the team will divide them into two groups (asymptomatic or healthy). Then the blood samples will be sent to the team of Jean Loup Lemesre of the Laboratory INTERTRYP - UMR177 of the IRD in Montpellier. ELISPOT analysis and assay of cytokines and proteases to describe the immune response of the two groups and to compare them. In addition, cell typing will be performed by flow cytometry to determine the type of lymphocytes involved in the immune response against Leishmania peptides. HLA typing will also be performed to validate the HLA coverage of the peptides tested. Finally, an analysis of the transcryptome will be carried out, which will allow to identify the differential expression of genes and metabolic pathways involved in the immune response and thus to understand how asymptomatic people can control the infection.

Study Overview

• Status: Completed
• Conditions: Leishmaniasis, Cutaneous
• Intervention / Treatment: Procedure: Blood sampling

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Nice, France, 06000
    • Nice hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria for asymptomatic careers

• Male and Female
• Age between 18 and 80 years
• PCR and western blot positive to L. Infantum (these exams will be redone as part of the study).
• Signature of informed consent
• Affiliation to a social security scheme

Exclusion Criteria:

• Presence of known immunosuppression or immunosuppressive therapy. -HIV-positive people will be excluded because of the immunosuppressive action of HIV on the immune system. HIV status will be determined by interrogation.
• Pregnant women will be excluded. A urinary pregnancy test (taken from the inclusion proposal) will be performed for women of child-bearing age. The results will be communicated to the patient by a doctor of her choice.
• Persons under guardianship

Inclusion Criteria for healthy patient

• Male or Female
• Age between 18 and 80 years
• PCR and western blot negative Leishmania (these exams will be redone as part of the study).
• Signature of informed consent
• Affiliation to a social security scheme

Exclusion Criteria:

• Presence of known immunosuppression or immunosuppressive therapy. -HIV-positive people will be excluded because of the immunosuppressive action of HIV on the immune system. HIV status will be determined by interrogation.
• Pregnant women will be excluded. A urinary pregnancy test (taken from the inclusion proposal) will be performed for women of child-bearing age. The results will be communicated to the patient by a doctor of her choice.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: NON_RANDOMIZED
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: asymptomatic carriers	Procedure: Blood sampling; sampling of 7 blood tubes
OTHER: uninfected patient	Procedure: Blood sampling; sampling of 7 blood tubes

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
immune response of lymphocytes from asymptomatic carriers	decription of immune response of lymphocytes from asymptomatic carriers after stimulation by Leishmania vaccine peptides in ex vivo ELIPSPOT: Presence or absence of immune response.	15 months

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Nice

Study record dates

Study Major Dates

• Study Start (ACTUAL): November 10, 2017
• Primary Completion (ACTUAL): November 10, 2017
• Study Completion (ACTUAL): September 1, 2021

Study Registration Dates

• First Submitted: October 3, 2017
• First Submitted That Met QC Criteria: October 3, 2017
• First Posted (ACTUAL): October 6, 2017

Study Record Updates

• Last Update Posted (ACTUAL): March 18, 2022
• Last Update Submitted That Met QC Criteria: March 17, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Infections; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Skin Diseases, Parasitic; Skin Diseases, Infectious; Euglenozoa Infections; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral
• Other Study ID Numbers: 17-AOI-04

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No